The firm now expects its cash runway to extend to 2028, bolstered by having recently raised $244 million via a private placement and an at-the-market issuance.

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.

The EMA's CHMP said the single pivotal US trial could serve as the basis for a marketing authorization application in the EU.

BUFFALO, NY – Five major research centers in New York have banded together to share resources and a manufacturing facility in ...

The firm is touting its AI-driven foundation model's ability to predict how any patient will respond to any drug, allowing sponsors to fine-tune their trials.

Kumquat, based in San Diego, received US Food and Drug Administration clearance of its investigational new drug application for the KRAS G12D inhibitor in July. The firm will be responsible for ...

The firm will explore FORX-428's activity in patients whose tumors harbor DNA damage repair mutations or mutations that cause high DNA replication stress.

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Patients on a combination of toripalimab and RemeGen's anti-HER2 antibody disitamab vedotin fared better than those on a chemotherapy regimen.

Fifteen percent of patients who received Skysona within clinical trials have since been diagnosed with hematologic malignancies.